[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100080988":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":17,"responsibleParty":7,"collaborators":30,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":40,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":7,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":58,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":7,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Meningococcal C Conjugate Vaccine",[13],{"name":14,"affiliation":15,"role":16},"Novartis - Information Services","Novartis Vaccines & Diagnostics","PRINCIPAL_INVESTIGATOR",[18],{"facility":19,"status":7,"city":20,"state":7,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Istituto di Pediatria, Università degli Studi di Milano","Milan","20122","Italy","IT",{"type":25,"coordinates":26},"Point",[27,28],12.59836,42.78235,{"lat":28,"lon":27},[31],{"name":32,"class":6},"Novartis Vaccines","100080988","phase-3-immunogenicity-safety-and-tolerability-of-chiron-meningococcal-c-conjugate-vaccine-administered-to-healthy-premature-and-non-premature-children-of-3-months-of-age-100080988",false,"NCT00310674","Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age","A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine","Inclusion Criteria:\n\n* Healthy children of 11 to 15 weeks of age\n\nExclusion Criteria:\n\n* Children who previously received any kind of Meningococcal C vaccine, DTaP-IPV-HBV-Hib vaccine or a Hepatitis B vaccine at birth\n* Children who have a previous ascertained or suspected disease caused by N. meningitidis, Corynebacterium diphtheriae, Clostridium tetani, poliovirus, Hepatitis B or H. influenzae type b, culture proven Bordetella pertussis, or clinical condition of spasmodic cough for a period longer than or equal to 2 weeks associated with apnea or whooping\n* Children who have had household contact with and\u002For intimate exposure to an individual with culture proven N. meningitidis serogroup C or Bordetella pertussis, within the previous 60 days",true,"ALL","11 Weeks","15 Weeks",{"count":45,"type":7},150,"INTERVENTIONAL",[48],"PHASE3","Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age",[51],"Prevention of Meningococcal Infection",[53,54,55,56,57],"Prevention of Meningococcal Meningitis","meningococcal vaccines","conjugate","Immunology","infant","COMPLETED","2007-03-12",{"date":61,"type":62},"2007-03-13","ESTIMATED",{"date":64,"type":7},"2004-09",{"name":5,"class":6},1]